Page last updated: 2024-07-31 17:45:53
ifetroban
Description
ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative [MeSH]
ifetroban : no description available [CHeBI]
Cross-References
Synonyms (28)
Synonym |
bms 180,291 |
gtpl1987 |
3-[2-[[(1s,4r,5s,6r)-5-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-6-yl]methyl]phenyl]propanoic acid |
143443-90-7 |
bms180291 |
benzenepropanoic acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, (1s-(exo,exo))- |
ifetroban |
bms-180291 |
ifetroban [usan:inn] |
bms 180291-02 |
bms 180291 |
o-((1s,2r,3s,4r)-3-(4-(pentylcarbamoyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)hydrocinnamic acid |
bdbm50212318 |
CHEBI:188730 |
3-[2-[[(1s,2r,3s,4r)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid |
unii-e833kt807k |
e833kt807k , |
CHEMBL3301673 |
SCHEMBL28135 |
o-[[1s,2r,3s,4r)-3-[4-(pentylcarbamoyl)-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]hydrocinnamic acid |
ifetroban [inn] |
ifetroban [usan] |
CS-0025381 |
HY-105218 |
DB12321 |
DTXSID40869931 |
Q5991162 |
AKOS040748563 |
Drug Classes (2)
Class | Description |
monocarboxylic acid | An oxoacid containing a single carboxy group. |
benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
Bioassays (17)
Assay ID | Title | Year | Journal | Article |
AID540219 | Volume of distribution at steady state in monkey after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 ISSN: 0022-3549 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
AID540214 | Clearance in rat after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 ISSN: 0022-3549 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
AID540217 | Volume of distribution at steady state in dog after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 ISSN: 0022-3549 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
AID540220 | Clearance in human after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 ISSN: 0022-3549 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
AID540215 | Volume of distribution at steady state in rat after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 ISSN: 0022-3549 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
AID540216 | Clearance in dog after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 ISSN: 0022-3549 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
AID540230 | Dose normalised AUC in rat after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 ISSN: 0049-8254 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
AID540221 | Volume of distribution at steady state in human after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 ISSN: 0022-3549 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
AID540231 | Dose normalised AUC in dog after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 ISSN: 0049-8254 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
AID540218 | Clearance in monkey after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 ISSN: 0022-3549 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
AID540232 | Dose normalised AUC in monkey after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 ISSN: 0049-8254 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
AID540233 | Dose normalised AUC in human after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 ISSN: 0049-8254 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
AID1346422 | Human TP receptor (Prostanoid receptors) | 1993 | The Journal of pharmacology and experimental therapeutics, Feb, Volume: 264, Issue:2 ISSN: 0022-3565 | Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. |
Research
Studies (44)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 29 (65.91) | 18.2507 |
2000's | 11 (25.00) | 29.6817 |
2010's | 3 (6.82) | 24.3611 |
2020's | 1 (2.27) | 2.80 |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 3 (6.67%) | 5.53% |
Reviews | 2 (4.44%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 40 (88.89%) | 84.16% |
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
dihydro-3-coumaric acid | | monocarboxylic acid | Escherichia coli metabolite; human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-phenylpropionic acid | | benzenes; monocarboxylic acid | antifungal agent; human metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(3-pyridine)acetic acid | | monocarboxylic acid; pyridines | human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gamma-aminobutyric acid | | amino acid zwitterion; gamma-amino acid; monocarboxylic acid | human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-hydroxyphenylacetic acid | | monocarboxylic acid; phenols | fungal metabolite; human metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetic acid | | monocarboxylic acid | antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
formic acid | | monocarboxylic acid | antibacterial agent; astringent; metabolite; protic solvent; solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aminooxyacetic acid | | amino acid; hydroxylamines; monocarboxylic acid | anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; nootropic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-oxo-4-(3-pyridyl)butanoic acid | | aromatic ketone; monocarboxylic acid; pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gamma-guanidinobutyric acid | | guanidines; monocarboxylic acid; zwitterion | fungal metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-aminocyclopropane-1-carboxylic acid | | amino acid zwitterion; monocarboxylic acid; non-proteinogenic alpha-amino acid | ethylene releasers; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphonoacetic acid | | monocarboxylic acid; phosphonic acids | antiviral agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5,6-dihydroorotate | | monocarboxylic acid; N-acylurea; pyrimidinemonocarboxylic acid; secondary amide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydantoin-5-propionic acid | | imidazolidine-2,4-dione; monocarboxylic acid | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
indoleacetic acid | | indole-3-acetic acids; monocarboxylic acid | auxin; human metabolite; mouse metabolite; plant hormone; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
melilotic acid | | monocarboxylic acid; phenols | bacterial xenobiotic metabolite; fungal xenobiotic metabolite; human xenobiotic metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylacetic acid | | benzenes; monocarboxylic acid; phenylacetic acids | allergen; Aspergillus metabolite; auxin; EC 6.4.1.1 (pyruvate carboxylase) inhibitor; Escherichia coli metabolite; human metabolite; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite; toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phosphoenolpyruvate | | carboxyalkyl phosphate; monocarboxylic acid | fundamental metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-(2,4-dichlorophenoxy)butyric acid | | aromatic ether; monocarboxylic acid; organochlorine compound | agrochemical; phenoxy herbicide; synthetic auxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
homovanillic acid | | guaiacols; monocarboxylic acid | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acemetacin | | carboxylic ester; indol-3-yl carboxylic acid; monocarboxylic acid; monochlorobenzenes; N-acylindole | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alminoprofen | | amino acid; monocarboxylic acid; secondary amino compound; substituted aniline | antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alpha-methyl-m-tyrosine | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
amlexanox | | monocarboxylic acid; pyridochromene | anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aristolochic acid i | | aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound | carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
baclofen | | amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound | central nervous system depressant; GABA agonist; muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bendazac | | indazoles; monocarboxylic acid | non-steroidal anti-inflammatory drug; radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
metrizoate | | monocarboxylic acid | radioopaque medium | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbidopa | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cetirizine | | ether; monocarboxylic acid; monochlorobenzenes; piperazines | anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cetraxate | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
chlorambucil | | aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound | alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
chrysanthemic acid | | cyclopropanes; monocarboxylic acid | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ciprofibrate | | cyclopropanes; monocarboxylic acid; organochlorine compound | antilipemic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
clofibric acid | | aromatic ether; monocarboxylic acid; monochlorobenzenes | anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diclofenac | | amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound | antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
enoxacin | | 1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic | antibacterial drug; DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ethacrynic acid | | aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
etodolac | | monocarboxylic acid; organic heterotricyclic compound | antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-biphenylylacetic acid | | biphenyls; monocarboxylic acid | non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fenoprofen | | monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fleroxacin | | difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines | antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
flurbiprofen | | fluorobiphenyl; monocarboxylic acid | antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ibuprofen | | monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ici 204448 | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
indoprofen | | gamma-lactam; isoindoles; monocarboxylic acid | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
iopanoic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ketorolac | | amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate | analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
loxoprofen | | cyclopentanones; monocarboxylic acid | antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
meclofenoxate | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sarkolysin | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mesalamine | | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-Hydroxy-alpha-methyl-DL-tyrosine | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nalidixic acid | | 1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic | antibacterial drug; antimicrobial agent; DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
oxonic acid | | 1,3,5-triazines; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
oxaprozin | | 1,3-oxazoles; monocarboxylic acid | analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
oxyphencyclimine | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-phenylbutyric acid | | monocarboxylic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pipemidic acid | | amino acid; monocarboxylic acid; N-arylpiperazine; pyridopyrimidine; quinolone antibiotic | antibacterial drug; DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
piromidic acid | | monocarboxylic acid; pyridopyrimidine; pyrrolidines; quinolone antibiotic; tertiary amino compound | antibacterial drug; DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
SU5402 | | monocarboxylic acid; oxindoles; pyrroles | fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
suprofen | | aromatic ketone; monocarboxylic acid; thiophenes | antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
suxibuzone | | hemisuccinate; monocarboxylic acid; pyrazolidines | antirheumatic drug; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tiaprofenic acid | | aromatic ketone; monocarboxylic acid; thiophenes | drug allergen; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tolmetin | | aromatic ketone; monocarboxylic acid; pyrroles | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tosufloxacin | | 1,8-naphthyridine derivative; amino acid; aminopyrrolidine; monocarboxylic acid; organofluorine compound; primary amino compound; quinolone antibiotic; tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tyropanoate | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
zomepirac | | aromatic ketone; monocarboxylic acid; monochlorobenzenes; pyrroles | cardiovascular drug; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trichloroacetic acid | | monocarboxylic acid; organochlorine compound | carcinogenic agent; metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dichloroacetic acid | | monocarboxylic acid; organochlorine compound | astringent; marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bis(p-chlorophenyl)acetic acid | | monocarboxylic acid; monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-phenylbutyric acid | | benzenes; monocarboxylic acid | human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mecoprop | | aromatic ether; monocarboxylic acid; monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fenoprop | | monocarboxylic acid | phenoxy herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
piperonylic acid | | aromatic carboxylic acid; benzodioxoles; monocarboxylic acid | antifungal agent; EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitor; plant metabolite; vulnerary | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-methyl-4-chlorophenoxy gamma-butyric acid | | aromatic ether; monocarboxylic acid; monochlorobenzenes | environmental contaminant; phenoxy herbicide; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
iophenoxic acid | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-methylvaleric acid | | branched-chain saturated fatty acid; methyl-branched fatty acid; monocarboxylic acid; short-chain fatty acid | flavouring agent; fragrance; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyclohexanecarboxylic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diphenylacetic acid | | monocarboxylic acid | xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dichlorprop | | aromatic ether; dichlorobenzene; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
amprotropine | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyanoacetic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
difluoroacetic acid | | monocarboxylic acid; organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-methylpyrazole-3-carboxylic acid | | monocarboxylic acid; pyrazoles | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hydantoic acid | | monocarboxylic acid; N-acylglycine; ureas | rat metabolite; xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
abietic acid | | abietane diterpenoid; monocarboxylic acid | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,5-dibromotyrosine | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-aminobutyric acid | | amino acid zwitterion; beta-amino acid; monocarboxylic acid | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-carboxybenzaladehyde | | benzaldehydes; benzoic acids; monocarboxylic acid | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-hydroxybenzeneacetic acid | | monocarboxylic acid; phenols | human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methoxyacetic acid | | ether; monocarboxylic acid | antineoplastic agent; apoptosis inducer; human xenobiotic metabolite; mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dibromoacetic acid | | 2-bromocarboxylic acid; monocarboxylic acid | apoptosis inducer; geroprotector; marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
hadacidin | | aldehyde; monocarboxylic acid; N-hydroxy-alpha-amino-acid | antimicrobial agent; antineoplastic agent; Penicillium metabolite; teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-hydroxypicolinic acid | | monocarboxylic acid; monohydroxypyridine | MALDI matrix material | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydroferulic acid | | guaiacols; monocarboxylic acid; phenylpropanoid | antioxidant; human xenobiotic metabolite; mouse metabolite; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ibufenac | | monocarboxylic acid | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyclopropanecarboxylic acid | | cyclopropanes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
(4-tert-Butyl-phenoxy)-acetic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-methoxyphenylacetic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-chlorophenylacetic acid | | monocarboxylic acid; monochlorobenzenes | xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-hydroxyphenoxyacetic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-phenylvaleric acid | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(4-chlorophenoxy)propionic acid | | monocarboxylic acid | phenoxy herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bumadizone | | carbohydrazide; monocarboxylic acid | antipyretic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenoxyacetic acid | | aromatic ether; monocarboxylic acid | allergen; Aspergillus metabolite; human xenobiotic metabolite; plant growth retardant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nafenopin | | aromatic ether; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-phenylbutyric acid | | benzenes; monocarboxylic acid | antibacterial agent; bacterial xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ochratoxin b | | isochromanes; monocarboxylic acid; N-acyl-L-phenylalanine; phenylalanine derivative | Aspergillus metabolite; calcium channel blocker; mycotoxin; Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyclohexaneacetic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glucoheptonate | | carbohydrate acid; monocarboxylic acid | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alclofenac | | aromatic ether; monocarboxylic acid; monochlorobenzenes | drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-methoxy-2-naphthylacetic acid | | methoxynaphthalene; monocarboxylic acid | drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
7-aminodesacetoxycephalosporanic acid | | cephalosporin; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbidopa | | catechols; hydrazines; monocarboxylic acid | antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
butyl(3-carboxypropyl)nitrosamine | | monocarboxylic acid; nitrosamine | carcinogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbidopa | | catechols; hydrate; hydrazines; monocarboxylic acid | antidyskinesia agent; antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ticrynafen | | aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes | antihypertensive agent; hepatotoxic agent; loop diuretic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(4-(2,4-dichlorophenoxy)phenoxy)propionic acid | | aromatic ether; dichlorobenzene; diether; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bezafibrate | | aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes | antilipemic drug; environmental contaminant; geroprotector; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lonidamine | | dichlorobenzene; indazoles; monocarboxylic acid | antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benoxaprofen | | 1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes | antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid | | chromanol; monocarboxylic acid; phenols | antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
triclopyr | | aromatic ether; chloropyridine; monocarboxylic acid | agrochemical; environmental contaminant; herbicide; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acifluorfen | | aromatic ether; benzoic acids; C-nitro compound; monocarboxylic acid; organochlorine compound; organofluorine compound | agrochemical; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4,5-amino-3,5-dichloro-6-fluoro-2-pyridinyloxyacetic acid | | aminopyridine; aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound | environmental contaminant; herbicide; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
haloxyfop | | aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound; pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pefloxacin | | fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone | antibacterial drug; antiinfective agent; DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
imazaquin | | imidazolone; monocarboxylic acid; quinolinemonocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
difloxacin | | fluoroquinolone antibiotic; monocarboxylic acid; monofluorobenzenes; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone | antibacterial drug; Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
brequinar | | biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid | anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
temafloxacin | | amino acid; monocarboxylic acid; N-arylpiperazine; organofluorine compound; quinolone antibiotic; quinolone; secondary amino compound; tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
adapalene | | adamantanes; monocarboxylic acid; naphthoic acid | dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
valsartan | | biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fenofibric acid | | aromatic ketone; chlorobenzophenone; monocarboxylic acid | drug metabolite; marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
salvin | | abietane diterpenoid; carbotricyclic compound; catechols; monocarboxylic acid | angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; food preservative; HIV protease inhibitor; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tetraiodothyroacetic acid | | 2-halophenol; aromatic ether; iodophenol; monocarboxylic acid | apoptosis inducer; human metabolite; thyroid hormone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
etofibrate | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fradafiban | | carboxamidine; monocarboxylic acid; pyrrolidin-2-ones | platelet glycoprotein-IIb/IIIa receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylacetylglycine | | monocarboxylic acid amide; monocarboxylic acid; N-acylglycine | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lonazolac | | monocarboxylic acid; monochlorobenzenes; pyrazoles | antineoplastic agent; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
miroprofen | | imidazopyridine; monocarboxylic acid | antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
flunoxaprofen | | 1,3-benzoxazoles; monocarboxylic acid; organofluorine compound | antirheumatic drug; hepatotoxic agent; non-steroidal anti-inflammatory drug; protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tianeptine | | dibenzothiazepine; monocarboxylic acid; organochlorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
binifibrate | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-imidazolepropionic acid | | imidazoles; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aceclofenac | | amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gr 117289 | | 1-benzofurans; biaryl; imidazolyl carboxylic acid; monocarboxylic acid; organobromine compound; organochlorine compound; tetrazoles | angiotensin receptor antagonist; antihypertensive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alborixin | | cyclic hemiketal; monocarboxylic acid; oxolanes; polyether antibiotic | ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
madecassic acid | | monocarboxylic acid; pentacyclic triterpenoid; tetrol | antioxidant; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
monotropein | | beta-D-glucoside; cyclopentapyran; iridoid monoterpenoid; monocarboxylic acid; monosaccharide derivative | anti-inflammatory agent; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-(3,4-dimethoxyphenyl)propanoic acid | | dimethoxybenzene; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-methylhippuric acid | | monocarboxylic acid; N-acylglycine | EC 1.1.1.21 (aldehyde reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methylimidazoleacetic acid | | imidazoles; monocarboxylic acid | GABA agonist; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-carboxyfluorescein | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-(2-thienyl)butyric acid | | monocarboxylic acid; thiophenes | hapten | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-(trimethylsilyl)propionic acid | | monocarboxylic acid; organosilicon compound | NMR chemical shift reference compound | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-(4'-hydroxyl-3',5'-dimethoxyphenyl)propionic acid | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ritalinic acid | | monocarboxylic acid; piperidines | drug metabolite; marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
indole-1-acetic acid | | indolyl carboxylic acid; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
(1-hydroxycyclopentyl)phenylacetic acid | | monocarboxylic acid; tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fluazifop | | aromatic ether; monocarboxylic acid; organofluorine compound; pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
quinclorac | | monocarboxylic acid; organochlorine compound; quinolinemonocarboxylic acid | agrochemical; herbicide; synthetic auxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gypsogenin | | aldehyde; monocarboxylic acid; pentacyclic triterpenoid; sapogenin | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
beta-hydroxyphenylpropionic acid | | 3-hydroxy carboxylic acid; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
salicylamide-2-acetic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dehydroabietic acid | | abietane diterpenoid; carbotricyclic compound; monocarboxylic acid | allergen; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2,6-dichloroisonicotinic acid | | monocarboxylic acid; organochlorine compound; pyridines | EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-phenazinecarboxylic acid | | aromatic carboxylic acid; monocarboxylic acid; phenazines | antifungal agent; antimicrobial agent; bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
imidazoleacetic acid | | imidazoles; monocarboxylic acid | metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2'-(2-hydroxyphenyl)-2'-thiazoline-4'-carboxylic acid | | imidothioate; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alpha-methylphenylalanine | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aristolochic acid ii | | aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound | carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4'-hydroxydiclofenac | | dichlorobenzene; monocarboxylic acid; phenols; secondary amino compound | allergen; drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
asiatic acid | | monocarboxylic acid; pentacyclic triterpenoid; triol | angiogenesis modulating agent; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bw 245c | | imidazolidine-2,4-dione; monocarboxylic acid; secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
piscidic acid | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mitiglinide | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
celastrol | | monocarboxylic acid; pentacyclic triterpenoid | anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-carboxyfluorescein | | monocarboxylic acid | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
vadimezan | | monocarboxylic acid; xanthones | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ectoine | | 1,4,5,6-tetrahydropyrimidines; carboxamidine; monocarboxylic acid; zwitterion | osmolyte | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
chrysobactin | | catechols; dipeptide; monocarboxylic acid; primary alcohol; primary amino compound | bacterial metabolite; siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cd 437 | | adamantanes; monocarboxylic acid; naphthoic acid; phenols | apoptosis inducer; retinoic acid receptor gamma agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
agn 190299 | | monocarboxylic acid; pyridines; retinoid; thiochromane | keratolytic drug; teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-bromotyrosine | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cox 189 | | amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound | cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
varespladib | | aromatic ether; benzenes; dicarboxylic acid monoamide; indoles; monocarboxylic acid; primary carboxamide | anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
naproxen | | methoxynaphthalene; monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
clofibride | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbazic acid | | monocarboxylic acid; one-carbon compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
endocrocin | | monocarboxylic acid; phenols; trihydroxyanthraquinone | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,5-diiodothyropropionic acid | | aromatic ether; monocarboxylic acid; organoiodine compound; phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aristolochic acid D | | aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound | carcinogenic agent; metabolite; nephrotoxin; toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,5-dihydroxyphenylpropionic acid | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetyl aleuritolic acid | | acetate ester; monocarboxylic acid; pentacyclic triterpenoid | antineoplastic agent; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fukiic acid | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
delta-1-piperidine-6-carboxylic acid | | monocarboxylic acid; tetrahydropyridine | mammalian metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aristolochic acid c | | aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound | carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-hydroxy-5-cholestenoic acid | | 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; cholestanoid; monocarboxylic acid; steroid acid | bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
enrasentan | | aromatic ether; benzodioxoles; indanes; monocarboxylic acid; monomethoxybenzene; primary alcohol | antihypertensive agent; endothelin receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
quizalofop | | aromatic ether; monocarboxylic acid; organochlorine compound; quinoxaline derivative | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
9-mercaptodethiobiotin | | imidazolidinone; monocarboxylic acid; thiol; ureas | Escherichia coli metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
proclavaminic acid | | amino acid zwitterion; azetidines; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
orantinib | | monocarboxylic acid; oxindoles; pyrroles | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
deferasirox | | benzoic acids; monocarboxylic acid; phenols; triazoles | iron chelator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sandaracopimaric acid | | monocarboxylic acid; pimarane diterpenoid; tricyclic diterpenoid | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
7-methoxycoumarin-4-acetic acid | | monocarboxylic acid | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
monensin | | cyclic hemiketal; monocarboxylic acid; polyether antibiotic; spiroketal | antifungal agent; coccidiostat; ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
isopimaric acid | | carbotricyclic compound; diterpenoid; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nanaomycin a | | benzoisochromanequinone; monocarboxylic acid; organooxygen heterocyclic antibiotic; p-quinones | bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
theogallin | | gallate ester; monocarboxylic acid; tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bispyribac | | aromatic ether; benzoic acids; monocarboxylic acid; pyrimidines | herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyochelin | | monocarboxylic acid; phenols; thiazolidines | metabolite; siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
yersiniabactin | | monocarboxylic acid; phenols; secondary alcohol; thiazolidines | bacterial metabolite; siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mycophenolic acid | | 2-benzofurans; gamma-lactone; monocarboxylic acid; phenols | anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mupirocin | | alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol | antibacterial drug; bacterial metabolite; protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gw 409544 | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
steviol | | bridged compound; ent-kaurane diterpenoid; monocarboxylic acid; tertiary allylic alcohol; tetracyclic diterpenoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bevirimat | | dicarboxylic acid monoester; monocarboxylic acid; pentacyclic triterpenoid | HIV-1 maturation inhibitor; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bromochloroacetic acid | | 2-bromocarboxylic acid; monocarboxylic acid; organochlorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
neurosporaxanthin | | apo carotenoid C35 terpenoid; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
canrenoic acid | | 3-oxo-Delta(4) steroid; monocarboxylic acid; steroid acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dexketoprofen | | benzophenones; monocarboxylic acid | cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(4-ethylphenoxy)acetic acid (4-nitrophenyl) ester | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[4-(pyridin-4-ylmethylsulfamoyl)phenoxy]acetic acid methyl ester | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[2-bromo-4-(hydroxymethyl)-6-methoxyphenoxy]acetic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulindac | | monocarboxylic acid; organofluorine compound; sulfoxide | analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
epalrestat | | monocarboxylic acid; thiazolidines | EC 1.1.1.21 (aldehyde reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(4-bromophenoxy)acetic acid (5-phenyl-1,3,4-oxadiazol-2-yl)methyl ester | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(2-cyanophenoxy)acetic acid [2-(2,5-dimethyl-1-prop-2-enyl-3-pyrrolyl)-2-oxoethyl] ester | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(4-formylphenoxy)acetic acid [2-(4-methylanilino)-4-thiazolyl]methyl ester | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[4-[2-(1-cyclohexenyl)ethylsulfamoyl]-2-methylphenoxy]acetic acid methyl ester | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-[4-(2-furylcarbonyl)piperazino]-5-oxo-3-phenylpentanoic acid | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
olivetolic acid | | benzoic acids; monocarboxylic acid; polyketide; resorcinols | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
helvolic acid | | 3-oxo-Delta(1) steroid; acetate ester; monocarboxylic acid; steroid acid | antibacterial agent; fungal metabolite; mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-oxopiperidine-2-carboxylate | | delta-lactam; monocarboxylic acid | bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-sulfinopropionic acid | | monocarboxylic acid; organosulfinic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
amibegron | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
chuangxinmycin | | indole alkaloid; monocarboxylic acid; thiinoindole | antibacterial agent; antimicrobial agent; bacterial metabolite; EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-hydroxydiclofenac | | dichlorobenzene; monocarboxylic acid; phenols; secondary amino compound | allergen; drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-oxindole-3-acetic acid | | indole-3-acetic acids; monocarboxylic acid; oxindoles | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | | adenosines; dicarboxylic acid monoamide; monocarboxylic acid | adenosine A2A receptor agonist; anti-inflammatory agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-phenyl-3-(1-tetrazolyl)propanoic acid | | benzenes; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gw 7647 | | aryl sulfide; monocarboxylic acid; ureas | PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
l 663536 | | aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes | antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
clopidogrel carboxylic acid | | monocarboxylic acid; monochlorobenzenes; tertiary amino compound; thienopyridine | drug metabolite; marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-methylene-2-octyl-5-oxo-3-oxolanecarboxylic acid | | gamma-lactone; monocarboxylic acid; tetrahydrofuranone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[4-(2,5-diphenyl-3,4-dihydropyrazol-3-yl)-2-methoxyphenoxy]acetic acid | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sm 21 | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[4-chloro-2-[3-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-2-yl]phenoxy]acetic acid methyl ester | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dinoprost | | monocarboxylic acid; prostaglandins Falpha | human metabolite; mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
montelukast | | aliphatic sulfide; monocarboxylic acid; quinolines | anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sofalcone | | aromatic ether; chalcones; monocarboxylic acid | anti-ulcer drug; antibacterial agent; gastrointestinal drug; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
16,16-dimethylprostaglandin e2 | | cyclopentanones; monocarboxylic acid; prostanoid; secondary allylic alcohol | anti-ulcer drug; gastrointestinal drug; radiation protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
iloprost | | carbobicyclic compound; monocarboxylic acid; secondary alcohol | platelet aggregation inhibitor; vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
rosmarinic acid | | carboxylic ester; monocarboxylic acid; phenylpropanoid; polyphenol | antioxidant; EC 1.1.1.21 (aldehyde reductase) inhibitor; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite; serine proteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
13,14-dihydroretinoic acid | | monocarboxylic acid; retinoid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulindac sulfide | | aryl sulfide; monocarboxylic acid; organofluorine compound | antineoplastic agent; apoptosis inducer; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lasalocid | | beta-hydroxy ketone; monocarboxylic acid; monohydroxybenzoic acid; oxanes; oxolanes; polyether antibiotic; secondary alcohol; tertiary alcohol | bacterial metabolite; coccidiostat; ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulindac sulfone | | monocarboxylic acid; organofluorine compound; sulfone | apoptosis inducer; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
clodinafop | | aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound; pyridines | EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; phenoxy herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
robenacoxib | | aromatic amino acid; monocarboxylic acid; organofluorine compound; phenylacetic acids; secondary amino compound | cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sdz eaa 494 | | monocarboxylic acid; olefinic compound; phosphonic acids; piperazinecarboxylic acid; tertiary amino compound | anticonvulsant; neuroprotective agent; NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
valerenic acid | | carbobicyclic compound; monocarboxylic acid; sesquiterpenoid | GABA modulator; plant metabolite; sedative; volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ici 215001 | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
beraprost | | enyne; monocarboxylic acid; organic heterotricyclic compound; secondary alcohol; secondary allylic alcohol | anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gemifloxacin | | 1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic | antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gw 501516 | | 1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound | carcinogenic agent; PPARbeta/delta agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
brl 37344 | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cp533536 | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mre 269 | | aromatic amine; ether; monocarboxylic acid; pyrazines; sulfonamide; tertiary amino compound | drug metabolite; orphan drug; platelet aggregation inhibitor; prostacyclin receptor agonist; vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gw0742 | | monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4alpha-methylergosta-8,24(28)-dien-3,7,11-trione-26-oic acid | | 11-oxo steroid; 3-oxo steroid; 7-oxo steroid; ergostanoid; monocarboxylic acid; steroid acid | anti-inflammatory agent; antineoplastic agent; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carmine | | C-glycosyl compound; monocarboxylic acid; tetrahydroxyanthraquinone | animal metabolite; histological dye | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ki16425 | | carbamate ester; isoxazoles; monocarboxylic acid; monochlorobenzenes; organic sulfide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
myrsinoic acid b | | 1-benzofurans; monocarboxylic acid | anti-inflammatory agent; EC 4.4.1.11 (methionine gamma-lyase) inhibitor; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
triptohypol C | | benzenediols; monocarboxylic acid; pentacyclic triterpenoid | apoptosis inducer; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
artemisic acid | | carbobicyclic compound; monocarboxylic acid; octahydronaphthalenes; sesquiterpenoid | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tafamidis | | 1,3-benzoxazoles; dichlorobenzene; monocarboxylic acid | central nervous system drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dihydroartemisinic acid | | carbobicyclic compound; monocarboxylic acid; octahydronaphthalenes; sesquiterpenoid | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
finafloxacin | | cyclopropanes; monocarboxylic acid; nitrile; organofluorine compound; quinolone; secondary amino compound; tertiary amino compound | antibacterial drug; antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyrostatin a | | 1,4,5,6-tetrahydropyrimidines; carboxamidine; iminium betaine; monocarboxylic acid; secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
roburic acid | | monocarboxylic acid; olefinic compound; tetracyclic triterpenoid | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
imidazoleacetic acid ribotide | | imidazoles; monocarboxylic acid; N-glycosyl compound; ribose monophosphate | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
vanchrobactin | | catechols; dipeptide; guanidines; monocarboxylic acid; primary alcohol; triol | bacterial metabolite; marine metabolite; siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
spongia-13(16),14-dien-19-oic acid | | cyclic ether; monocarboxylic acid; tetracyclic diterpenoid | androgen antagonist; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cathestatin b | | dicarboxylic acid monoamide; epoxide; monocarboxylic acid; phenols; primary amino compound | antimicrobial agent; cysteine protease inhibitor; Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
borrelidin | | aliphatic nitrile; diol; macrolide; monocarboxylic acid; secondary alcohol | antifungal agent; antimalarial; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
germacra-1(10),4,11(13)-trien-12-oic acid | | germacrane sesquiterpenoid; monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ascr#5 | | monocarboxylic acid; omega-hydroxy fatty acid ascaroside | Caenorhabditis elegans metabolite; pheromone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tropodithietic acid | | cyclic ketone; monocarboxylic acid; organic disulfide; organic heterobicyclic compound; organosulfur heterocyclic compound | antibacterial agent; bacterial metabolite; marine metabolite; signalling molecule; toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fumimycin | | 1-benzofurans; dicarboxylic acid monoamide; gamma-lactone; monocarboxylic acid; polyphenol | antibacterial agent; Aspergillus metabolite; EC 3.5.1.88 (peptide deformylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3alpha,12alpha-dihydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | | 11-oxo steroid; 12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7-oxo steroid; monocarboxylic acid; secondary alpha-hydroxy ketone; steroid acid | antineoplastic agent; metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | | 11-oxo steroid; 3alpha-hydroxy steroid; 7-oxo steroid; monocarboxylic acid; steroid acid | antineoplastic agent; cholinergic antagonist; metabolite; serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lesinurad | | aryl sulfide; cyclopropanes; monocarboxylic acid; naphthalenes; organobromine compound; triazoles | uricosuric drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
saroglitazar | | aromatic ether; methyl sulfide; monocarboxylic acid; pyrroles | hypoglycemic agent; PPARalpha agonist; PPARgamma agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gsk2879552 | | benzenes; benzoic acids; cyclopropanes; monocarboxylic acid; piperidines; secondary amino compound; tertiary amino compound | antineoplastic agent; EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzene | | aromatic annulene; benzenes; volatile organic compound | carcinogenic agent; environmental contaminant; non-polar solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gallopamil | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mandelic acid | | 2-hydroxy monocarboxylic acid; benzenes | antibacterial agent; human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-phenyl-3-furoxancarbonitrile | | 1,2,5-oxadiazole; benzenes; N-oxide; nitrile | geroprotector; nitric oxide donor; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bencyclane | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzamidine | | benzenes; carboxamidine | serine protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzyl isothiocyanate | | benzenes; isothiocyanate | antibacterial drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzylhydrochlorothiazide | | benzenes; benzothiadiazine; organochlorine compound; secondary amino compound; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbetapentane | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
chlorpropham | | benzenes; carbamate ester; monochlorobenzenes | herbicide; plant growth retardant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cimaterol | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
clofilium | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diphenidol | | benzenes; piperidines; tertiary alcohol | antiemetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cycloadiphenine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fenipentol | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
lidocaine | | benzenes; monocarboxylic acid amide; tertiary amino compound | anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
isocarboxazid | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
labetalol | | benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methadone | | benzenes; diarylmethane; ketone; tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
metolachlor | | aromatic amide; benzenes; ether; organochlorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nafoxidine | | benzenes; naphthalenes; ring assembly | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nicardipine | | benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenprobamate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulfabenzamide | | benzenes; sulfonamide antibiotic; sulfonamide | antibacterial drug; antimicrobial drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulfacytine | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulfamonomethoxine | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulfaquinoxaline | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-phenylcyclopropan-1-amine | | benzenes; cyclopropanes; primary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tolazoline hydrochloride | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylethyl alcohol | | benzenes; primary alcohol | Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mebanazine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phencyclidine | | benzenes; piperidines | anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
caramiphen | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
acetyl sulfisoxazole | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diphenyl | | aromatic fungicide; benzenes; biphenyls | antifungal agrochemical; antimicrobial food preservative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
styrene glycol | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulfaethidole | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzotrichloride | | benzenes; organochlorine compound; volatile organic compound | carcinogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzal chloride | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzoyl chloride | | acyl chloride; benzenes | carcinogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzonitrile | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methylphenylsulfide | | aryl sulfide; benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methyl phenylacetate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ethyl phenylacetate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenyl isocyanate | | benzenes; isocyanates | allergen; hapten | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-phenylpropanal | | aldehyde; benzenes | flavouring agent; plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,4-diethylbenzene | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzyl cyanide | | benzenes; nitrile | animal metabolite; pheromone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pivalylbenzhydrazine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mexacarbate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carbutamide | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methaphenilene | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
biphenylacetylene | | arylacetylene; benzenes | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
beclamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
mepiperphenidol | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glybuthiazol | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylacetylene | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulfanilylurea | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
metahexamide | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
nitrosobenzene | | benzenes; nitroso compound | xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
triphenylphosphine | | benzenes; tertiary phosphine | NMR chemical shift reference compound; reducing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-cyanophenol | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bensulide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-phenylcyclohex-1-ene | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
diphenyl disulfide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-phenylpropanol | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methyl phenyl sulfoxide | | benzenes; sulfoxide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2,6-dimethoxybenzoic acid | | benzenes; carbonyl compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylphosphonic acid | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pyrazon | | benzenes; organochlorine compound; primary amino compound; pyridazinone | environmental contaminant; herbicide; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-phenylpropylamine | | benzenes; phenylalkylamine; primary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
aminorex | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bitoscanate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
teclozan | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dioxacarb | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
fenestrel | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
propham | | benzenes; carbamate ester | herbicide; plant growth retardant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyanophenphos | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N'-methyl-N,N-diphenylurea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
dibenzo-18-crown-6 | | benzenes; crown ether | phase-transfer catalyst | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
clobutinol | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenyl acetate | | benzenes; phenyl acetates | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ripazepam | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
u 40481 | | benzenes; formamidines | marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
iprodione | | benzenes; dichlorophenyl dicarboximide fungicide; imidazole fungicide; imidazolidine-2,4-dione; ureas | antifungal agrochemical; nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
clorsulon | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ibutilide | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
prosulfocarb | | benzenes; monothiocarbamic ester | environmental contaminant; herbicide; xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
Isopropyl phenylacetate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-methyl-1-phenylpentan-2-ol | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
magnesium salicylate | | benzenes; carbonyl compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
plerixafor | | azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound | anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
tribuzone | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylpropiolic acid | | acetylenic compound; alpha,beta-unsaturated monocarboxylic acid; benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-Oxo-4-phenylbutyric acid | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
emopamil | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bathophenanthroline | | benzenes; phenanthrolines | chelator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-aminobenzenesulfonamide | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-phenylpropyl isothiocyanate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-chloro-5-sulfamoylanthranilic acid | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylheptatriyne | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
methyl mandelate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzylphosphonic acid | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
9,10-bis(phenylethynyl)anthracene | | anthracenes; arylacetylene; benzenes | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-phenylbutylamine | | benzenes; phenylalkylamine; primary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sdds | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-hydroxy-1-phenyl-2-propanone | | benzenes; methyl ketone; secondary alpha-hydroxy ketone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
silomat | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylisopropyladenosine | | aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound | adenosine A1 receptor agonist; neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
alpha-Cyclohexylmandelic acid | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-amino-1-phenylmethyl phosphonic acid | | benzenes; phosphonic acids; primary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-(4-(7-diethylamino-4-methylcoumarin-3-yl)phenyl)maleimide | | benzenes; coumarins; maleimides; tertiary amino compound | fluorescent dye | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-phenylbutyl isothiocyanate | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-acetylphenelzine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
forasartan | | benzenes; pyridines; tetrazoles; triazoles | angiotensin receptor antagonist; antihypertensive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
desethyloxybutynin | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
monodesmethylcitalopram | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cyclodrine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
didesmethylcitalopram | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
carlina oxide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-butyl-4-(hydroxymethyl)-1,2-diphenylpyrazolidine-3,5-dione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[(3-oxo-1-cyclohexenyl)amino]benzonitrile | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
benzyl d-glucopyranoside | | benzenes; beta-D-glucoside | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
cafenstrole | | benzenes; sulfone; triazoles | agrochemical; antimitotic; herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
(5-Phenyl-1,2,4-triazol-3-yl)urea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
pifithrin mu | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(2-phenylethyl)chromone | | benzenes; chromones | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bms 214662 | | benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes | antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-bis(N-methylanilino)phosphoryl-N-methylaniline | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-[di(propan-2-yl)phosphorylmethyl]benzonitrile | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4,5-diphenyl-1,2,3-triazole | | benzenes; ring assembly; triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-benzylquinazolin-4-amine | | benzenes; quinazolines; secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-acetyl-6-amino-8-(2-phenylethyl)-1,3,8,8a-tetrahydroisoquinoline-5,7,7-tricarbonitrile | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
thiobenzamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-(benzylsulfanyl)thieno[2,3-d]pyrimidine | | aryl sulfide; benzenes; thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-[(4-chloro-5-dithiazolylidene)amino]benzonitrile | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-methyl-N-phenylthiourea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,6-dibenzyl-1,2-dihydro-1,2,4,5-tetraazine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-cyclohexyl-3-(2-phenylethyl)urea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-ethyl-1-(phenylmethyl)-1,3,5-triazinane-2-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-amino-N-(4-ethoxyphenyl)benzenesulfonamide | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-[5-(phenylmethyl)-1,3,4-thiadiazol-2-yl]carbamic acid methyl ester | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,3-bis(2-phenylethyl)thiourea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
8-methyl-2-phenyl-1,2,4-triazaspiro[4.5]decane-3-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-(4-ethyl-5-methyl-3-thiophenyl)-4-(phenylmethyl)-1H-1,2,4-triazole-5-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-(phenylmethyl)-3-(5-propyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
6-(2-phenylethyl)-3-(phenylmethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole | | benzenes; triazolothiadiazole | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-(2-furanylmethyl)-3-(phenylmethyl)-1H-1,2,4-triazole-5-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-(1H-imidazol-1-ylmethyl)benzonitrile | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-(3-cyano-5-methyl-4-phenyl-2-thiophenyl)-3,5-dimethyl-4-isoxazolecarboxamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-amino-3-[3-(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)phenyl]thiourea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-(3-phenylpropyl)methanesulfonamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-[[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-sulfanylidenemethyl]-5-methyl-3-phenyl-4-isoxazolecarboxamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
amn082 | | benzenes; diamine; diarylmethane; secondary amino compound | metabotropic glutamate receptor agonist; neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(2-furanyl)-3,5-dimethyl-4-oxido-6-phenylpyrazin-1-ium 1-oxide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-(3,4-dihydro-2H-pyrrol-5-yl)-5-phenyl-1,3,4-oxadiazol-2-amine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-butyl-3-(phenylmethyl)-1H-1,2,4-triazole-5-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N1-phenethylhydrazine-1-carbothioamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-hydroxy-5,5-dimethyl-2-phenyltetrahydro-4H-imidazole-4-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[1-[2-oxo-2-[(4-thiophen-2-ylphenyl)methylamino]ethyl]cyclohexyl]acetic acid | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-(cyclopropylmethyl)-N'-phenylurea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[(4-chlorophenyl)methoxy]-6-methoxybenzonitrile | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-(4-pentylphenyl)acetic acid | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-methyl-2-phenyl-5-(2-phenylethyl)-1,2,4-triazolidine-3-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
k 858 | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-[[[4-(2-furanylmethyl)-5-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]thio]methyl]benzonitrile | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
9-oxo-N-(1-phenylethyl)-3-bicyclo[3.3.1]nonanecarboxamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N1,N4-bis(1-phenylethyl)cyclohexane-1,4-dicarboxamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-phenyl-3H-thiazole-2-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sulfatolamide | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-[(2-ethyl-4-hydroxy-4-methyl-1-oxopentyl)amino]-3-phenylthiourea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
2-[6-amino-5-cyano-4-(4-ethylphenyl)-2,4-dihydropyrano[2,3-c]pyrazol-3-yl]acetic acid methyl ester | | benzenes; pyranopyrazole | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3,5-dimethyl-N-(2-phenylethyl)-N-(phenylmethyl)-4-isoxazolesulfonamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-3-nitrobenzenesulfonamide | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N'-[5-(phenylmethyl)-4,5-dihydrothiazol-2-yl]hexanehydrazide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-amino-2-(diethylamino)-N-(2-methoxyphenyl)benzenesulfonamide | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-(1-phenylethyl)-3-(5-propyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | | benzenes; thiadiazolidine | anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-[[(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-sulfanylidenemethyl]-5-methyl-3-phenyl-4-isoxazolecarboxamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-[2-(4-methoxyphenyl)ethyl]-2-nitro-4-(1-pyrrolidinylsulfonyl)aniline | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-(1-adamantyl)-3-[1-(phenylmethyl)-4-pyrazolyl]urea | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
neticonazole | | aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide | antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
l796778 | | benzenes; C-nitro compound; L-lysine derivative; L-phenylalanine derivative; methyl ester; oligopeptide; secondary carboxamide; ureas | somatostatin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
l803087 | | benzenes; fluoroindole; guanidines; L-arginine derivative; methyl ester; phenylindole; secondary carboxamide | somatostatin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ro 4-6790 | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bay 11-7085 | | benzenes; nitrile; sulfone | anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
gluconasturtiin | | aralkylglucosinolic acid; benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
DPI2 | | benzenes; morpholines; secondary carboxamide; tertiary amino compound; thiazolidinone | ferroptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
l 744832 | | benzenes; ether; isopropyl ester; secondary carboxamide; sulfone; thiol | antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
glucotropeolin | | aralkylglucosinolic acid; benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-(4-phenylbutoxy)psoralen | | aromatic ether; benzenes; psoralens | geroprotector; immunosuppressive agent; potassium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ro 25-6981 | | benzenes; phenols; piperidines; secondary alcohol; tertiary amino compound | anticonvulsant; antidepressant; neuroprotective agent; NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bm 567 | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
varespladib methyl | | aromatic ether; benzenes; indoles; methyl ester; primary carboxamide | anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor; prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
npi 2358 | | 2,5-diketopiperazines; benzenes; imidazoles; olefinic compound | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
chlorobactene | | benzenes; carotenoid phi-end group; carotenoid | bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ws-5995 c | | benzenes; naphthalenes; ring assembly | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phevalin | | benzenes; pyrazinone | bacterial metabolite; calpain inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
np 031112 | | benzenes; naphthalenes; thiadiazolidine | anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
ym 216391 | | 1,3-oxazoles; 1,3-thiazoles; azamacrocycle; benzenes; heterodetic cyclic peptide | antineoplastic agent; bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-(4-nitrophenyl)-N-(4-phenylbutyl)-5-(phenylmethyl)-4,6-dihydro-3aH-pyrrolo[3,4-d]isoxazole-6a-carboxamide | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
SYC-435 | | benzenes; cyclic hydroxamic acid; pyridone | antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
trelagliptin | | benzenes; nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-hydroxy-5-nitro-N-(2-phenylethyl)-4-spiro[benzimidazole-2,1'-cyclohexane]imine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-methyl-5-pentyl-2-phenyl-1,2,4-triazolidine-3-thione | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
N-methyl-3-[5-(3-phenylpropyl)-1,3,4-oxadiazol-2-yl]-N-(3-thiophenylmethyl)propanamide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
(5S)-1-(4-cyclohexylbutyl)-5-phenyl-4,5-dihydroimidazol-2-amine | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
phenylmercuric acetate | | arylmercury compound; benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
sm 164 | | benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles | antineoplastic agent; apoptosis inducer; radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
5-Methyl-1-phenyl-3-hexanyl sulfamate | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1-(3-methoxyphenyl)-3-(4-phenylbutyl)urea | | benzenes; organic amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
niraparib | | benzenes; indazoles; piperidines; primary carboxamide | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
1,1,1,2,2-pentafluoro-7-phenylheptan-3-one | | benzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline | | benzenes; sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
difenacoum | | benzenes; naphthalenes; ring assembly | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
warfarin | | benzenes; hydroxycoumarin; methyl ketone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
bromfenacoum | | benzenes; naphthalenes; ring assembly | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
flocoumafen | | benzenes; naphthalenes; ring assembly | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
quinacrine | | acridines; aromatic ether; organochlorine compound; tertiary amino compound | antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
coumarin | | coumarins | fluorescent dye; human metabolite; plant metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
1-aminocyclopropane-1-carboxylic acid | | amino acid zwitterion; monocarboxylic acid; non-proteinogenic alpha-amino acid | ethylene releasers; plant metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
aminocaproic acid | | amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid | antifibrinolytic drug; hematologic agent; metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
1-(3-chlorophenyl)piperazine | | monochlorobenzenes; N-arylpiperazine | drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
enprofylline | | oxopurine | anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
phenytoin | | imidazolidine-2,4-dione | anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tacrine | | acridines; aromatic amine | EC 3.1.1.7 (acetylcholinesterase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
acebutolol | | aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound | anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
acetaminophen | | acetamides; phenols | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
acetazolamide | | monocarboxylic acid amide; sulfonamide; thiadiazoles | anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
albuterol | | phenols; phenylethanolamines; secondary amino compound | beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
alfuzosin | | monocarboxylic acid amide; quinazolines; tetrahydrofuranol | alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
alosetron | | imidazoles; pyridoindole | antiemetic; gastrointestinal drug; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
alprazolam | | organochlorine compound; triazolobenzodiazepine | anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
alprenolol | | secondary alcohol; secondary amino compound | anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amantadine | | adamantanes; primary aliphatic amine | analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
diatrizoic acid | | acetamides; benzoic acids; organoiodine compound | environmental contaminant; radioopaque medium; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
theophylline | | dimethylxanthine | adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amiodarone | | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amitriptyline | | carbotricyclic compound; tertiary amine | adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amlodipine | | dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound | antihypertensive agent; calcium channel blocker; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amsacrine | | acridines; aromatic ether; sulfonamide | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
antipyrine | | pyrazolone | antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
aspirin | | benzoic acids; phenyl acetates; salicylates | anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
atenolol | | ethanolamines; monocarboxylic acid amide; propanolamine | anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
azelastine | | monochlorobenzenes; phthalazines; tertiary amino compound | anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
betaxolol | | propanolamine | antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bevantolol | | propanolamine | anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
biperiden | | piperidines; tertiary alcohol; tertiary amino compound | antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bisoprolol | | secondary alcohol; secondary amine | anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bromazepam | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bromopride | | benzamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
brotizolam | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
buflomedil | | aromatic ketone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bumetanide | | amino acid; benzoic acids; sulfonamide | diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bunazosin | | quinazolines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bupivacaine | | aromatic amide; piperidinecarboxamide; tertiary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
busulfan | | methanesulfonate ester | alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
caffeine | | purine alkaloid; trimethylxanthine | adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
verapamil | | aromatic ether; nitrile; polyether; tertiary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
metrizoate | | monocarboxylic acid | radioopaque medium | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
carmustine | | N-nitrosoureas; organochlorine compound | alkylating agent; antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
carvedilol | | carbazoles; secondary alcohol; secondary amino compound | alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlorambucil | | aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound | alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlordiazepoxide | | benzodiazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chloroquine | | aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound | anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlorpheniramine | | monochlorobenzenes; pyridines; tertiary amino compound | anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlorpromazine | | organochlorine compound; phenothiazines; tertiary amine | anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlorpropamide | | monochlorobenzenes; N-sulfonylurea | hypoglycemic agent; insulin secretagogue | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlorthalidone | | isoindoles; monochlorobenzenes; sulfonamide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cifenline | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cimetidine | | aliphatic sulfide; guanidines; imidazoles; nitrile | adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ciprofloxacin | | aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion | antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
citalopram | | 2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound | | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
clomipramine | | dibenzoazepine | anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
clonazepam | | 1,4-benzodiazepinone; monochlorobenzenes | anticonvulsant; anxiolytic drug; GABA modulator | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
clonidine | | clonidine; imidazoline | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlorazepate | | 1,4-benzodiazepinone | anticonvulsant; anxiolytic drug; GABA modulator; prodrug | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
dapsone | | substituted aniline; sulfone | anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
desipramine | | dibenzoazepine; secondary amino compound | adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nordazepam | | 1,4-benzodiazepinone; organochlorine compound | anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amphetamine | | primary amine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
diazepam | | 1,4-benzodiazepinone; organochlorine compound | anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
diazoxide | | benzothiadiazine; organochlorine compound; sulfone | antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
diclofenac | | amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound | antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
diflunisal | | monohydroxybenzoic acid; organofluorine compound | non-narcotic analgesic; non-steroidal anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
diphenhydramine | | ether; tertiary amino compound | anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
disopyramide | | monocarboxylic acid amide; pyridines; tertiary amino compound | anti-arrhythmia drug | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
valproic acid | | branched-chain fatty acid; branched-chain saturated fatty acid | anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
domperidone | | benzimidazoles; heteroarylpiperidine | antiemetic; dopaminergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
doxapram | | morpholines; pyrrolidin-2-ones | central nervous system stimulant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
doxazosin | | aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines | alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
doxepin | | dibenzooxepine; tertiary amino compound | antidepressant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dyphylline | | oxopurine; propane-1,2-diols | bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
enoxacin | | 1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic | antibacterial drug; DNA synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ethacrynic acid | | aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ethosuximide | | dicarboximide; pyrrolidinone | anticonvulsant; geroprotector; T-type calcium channel blocker | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
etilefrine | | phenols | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
felodipine | | dichlorobenzene; dihydropyridine; ethyl ester; methyl ester | anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
berotek | | resorcinols; secondary alcohol; secondary amino compound | beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fenspiride | | azaspiro compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fentanyl | | anilide; monocarboxylic acid amide; piperidines | adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
flecainide | | aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines | anti-arrhythmia drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fleroxacin | | difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines | antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
fluconazole | | conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug | environmental contaminant; P450 inhibitor; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
flucytosine | | aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone | prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
flumazenil | | ethyl ester; imidazobenzodiazepine; organofluorine compound | antidote to benzodiazepine poisoning; GABA antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
flunitrazepam | | 1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes | anxiolytic drug; GABAA receptor agonist; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fluorescite | | benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye | fluorescent dye; radioopaque medium | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fluorouracil | | nucleobase analogue; organofluorine compound | antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
flurbiprofen | | fluorobiphenyl; monocarboxylic acid | antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
foscarnet | | carboxylic acid; one-carbon compound; phosphonic acids | antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
furosemide | | chlorobenzoic acid; furans; sulfonamide | environmental contaminant; loop diuretic; xenobiotic | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
gabapentin | | gamma-amino acid | anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
glimepiride | | sulfonamide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
glipizide | | aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines | EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
glyburide | | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
granisetron | | aromatic amide; indazoles | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
guanfacine | | acetamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
haloperidol | | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hexobarbital | | barbiturates | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hydralazine | | azaarene; hydrazines; ortho-fused heteroarene; phthalazines | antihypertensive agent; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hydroflumethiazide | | benzothiadiazine; thiazide | antihypertensive agent; diuretic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hydroxychloroquine | | aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound | anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hydroxyurea | | one-carbon compound; ureas | antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hypericin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ibuprofen | | monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lidocaine | | benzenes; monocarboxylic acid amide; tertiary amino compound | anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
ifosfamide | | ifosfamides | alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
imipramine | | dibenzoazepine | adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amrinone | | bipyridines | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
indomethacin | | aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole | analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
iohexol | | benzenedicarboxamide; organoiodine compound | environmental contaminant; radioopaque medium; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
iopromide | | dicarboxylic acid diamide; organoiodine compound | environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
iothalamic acid | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
avapro | | azaspiro compound; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
isoniazid | | carbohydrazide | antitubercular agent; drug allergen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
isoproterenol | | catechols; secondary alcohol; secondary amino compound | beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
isradipine | | benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
itraconazole | | piperazines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ketamine | | cyclohexanones; monochlorobenzenes; secondary amino compound | analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ketanserin | | aromatic ketone; organofluorine compound; piperidines; quinazolines | alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ketoprofen | | benzophenones; oxo monocarboxylic acid | antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ketorolac | | amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate | analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
labetalol | | benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lansoprazole | | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
letrozole | | nitrile; triazoles | antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lorazepam | | benzodiazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
losartan | | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
maprotiline | | anthracenes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mebendazole | | aromatic ketone; benzimidazoles; carbamate ester | antinematodal drug; microtubule-destabilising agent; tubulin modulator | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
meperidine | | ethyl ester; piperidinecarboxylate ester; tertiary amino compound | antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
mepivacaine | | piperidinecarboxamide | drug allergen; local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
meprobamate | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mesalamine | | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
metformin | | guanidines | environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methadone | | benzenes; diarylmethane; ketone; tertiary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methapyrilene | | ethylenediamine derivative | anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methylphenidate | | beta-amino acid ester; methyl ester; piperidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
metoclopramide | | benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound | antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
metolazone | | organochlorine compound; quinazolines; sulfonamide | antihypertensive agent; diuretic; ion transport inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
metoprolol | | aromatic ether; propanolamine; secondary alcohol; secondary amino compound | antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
metronidazole | | C-nitro compound; imidazoles; primary alcohol | antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mexiletine | | aromatic ether; primary amino compound | anti-arrhythmia drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
midazolam | | imidazobenzodiazepine; monofluorobenzenes; organochlorine compound | anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
milrinone | | bipyridines; nitrile; pyridone | cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mirtazapine | | benzazepine; tetracyclic antidepressant | alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mitoxantrone | | dihydroxyanthraquinone | analgesic; antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
moclobemide | | benzamides; monochlorobenzenes; morpholines | antidepressant; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
acecainide | | acetamides; benzamides | anti-arrhythmia drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
naratriptan | | heteroarylpiperidine; sulfonamide; tryptamines | serotonergic agonist; vasoconstrictor agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nefazodone | | aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles | alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nefopam | | benzoxazocine; tertiary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nevirapine | | cyclopropanes; dipyridodiazepine | antiviral drug; HIV-1 reverse transcriptase inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nicardipine | | benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound | | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
nifedipine | | C-nitro compound; dihydropyridine; methyl ester | calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nimodipine | | 2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester | antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
nisoldipine | | C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
nitrazepam | | 1,4-benzodiazepinone; C-nitro compound | anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nitrendipine | | C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester | antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nizatidine | | 1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound | anti-ulcer drug; cholinergic drug; H2-receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nomifensine | | isoquinolines | dopamine uptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nortriptyline | | organic tricyclic compound; secondary amine | adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ofloxacin | | 3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
omeprazole | | aromatic ether; benzimidazoles; pyridines; sulfoxide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ondansetron | | carbazoles | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
oxaprozin | | 1,3-oxazoles; monocarboxylic acid | analgesic; non-steroidal anti-inflammatory drug | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
oxazepam | | 1,4-benzodiazepinone; organochlorine compound | anxiolytic drug; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
oxiracetam | | organonitrogen compound; organooxygen compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
oxybutynin | | acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound | antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pamidronate | | phosphonoacetic acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pantoprazole | | aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
papaverine | | benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines | antispasmodic drug; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pentamidine | | aromatic ether; carboxamidine; diether | anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pentobarbital | | barbiturates | GABAA receptor agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pentoxifylline | | oxopurine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
perphenazine | | N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines | antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
phenacetin | | acetamides; aromatic ether | cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
phenobarbital | | barbiturates | anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
moxonidine | | organohalogen compound; pyrimidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pimobendan | | benzimidazoles; pyridazinone | cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pindolol | | indoles; secondary amine | antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
piretanide | | aromatic ether | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
prazosin | | aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines | alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
prilocaine | | amino acid amide; monocarboxylic acid amide | anticonvulsant; local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
primaquine | | aminoquinoline; aromatic ether; N-substituted diamine | antimalarial | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
probenecid | | benzoic acids; sulfonamide | uricosuric drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
procainamide | | benzamides | anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
prochlorperazine | | N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines | alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
procyclidine | | pyrrolidines; tertiary alcohol | antidyskinesia agent; antiparkinson drug; muscarinic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
promazine | | phenothiazines; tertiary amine | antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
promethazine | | phenothiazines; tertiary amine | anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
propafenone | | aromatic ketone; secondary alcohol; secondary amino compound | anti-arrhythmia drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
propofol | | phenols | anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
propranolol | | naphthalenes; propanolamine; secondary amine | anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
pyridostigmine | | pyridinium ion | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pyrimethamine | | aminopyrimidine; monochlorobenzenes | antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
rabeprazole | | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ranitidine | | aralkylamine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
risperidone | | 1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine | alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
rizatriptan | | tryptamines | anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sulfadiazine | | pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide | antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
risedronic acid | | pyridines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sotalol | | ethanolamines; secondary alcohol; secondary amino compound; sulfonamide | anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
imatinib | | aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines | antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
vorinostat | | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sulfamethoxazole | | isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide | antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sulfinpyrazone | | pyrazolidines; sulfoxide | uricosuric drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sulfisoxazole | | isoxazoles; sulfonamide antibiotic; sulfonamide | antibacterial drug; drug allergen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sumatriptan | | sulfonamide; tryptamines | serotonergic agonist; vasoconstrictor agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
suprofen | | aromatic ketone; monocarboxylic acid; thiophenes | antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
suramin | | naphthalenesulfonic acid; phenylureas; secondary carboxamide | angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gatifloxacin | | N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone | antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
temozolomide | | imidazotetrazine; monocarboxylic acid amide; triazene derivative | alkylating agent; antineoplastic agent; prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
terazosin | | furans; piperazines; primary amino compound; quinazolines | alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
terbutaline | | phenylethanolamines; resorcinols | anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
thalidomide | | phthalimides; piperidones | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
thiotepa | | aziridines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tinidazole | | imidazoles | antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tizanidine | | benzothiadiazole; imidazoles | alpha-adrenergic agonist; muscle relaxant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tolbutamide | | N-sulfonylurea | human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ultram | | aromatic ether; tertiary alcohol; tertiary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tranexamic acid | | amino acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
trazodone | | monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine | adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
triamterene | | pteridines | diuretic; sodium channel blocker | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
triazolam | | triazolobenzodiazepine | sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
trimethadione | | oxazolidinone | anticonvulsant; geroprotector | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
trimethoprim | | aminopyrimidine; methoxybenzenes | antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
trimetrexate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
trimipramine | | dibenzoazepine; tertiary amino compound | antidepressant; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
troglitazone | | chromanes; thiazolidinone | anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
urapidil | | piperazines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
venlafaxine | | cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound | adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
viloxazine | | aromatic ether | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zaleplon | | nitrile; pyrazolopyrimidine | anticonvulsant; anxiolytic drug; central nervous system depressant; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zolpidem | | imidazopyridine | central nervous system depressant; GABA agonist; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zonisamide | | 1,2-benzoxazoles; sulfonamide | anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zopiclone | | monochloropyridine; pyrrolopyrazine | central nervous system depressant; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
prednisolone | | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cephaloridine | | beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
prednisone | | 11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
penicillin g | | penicillin allergen; penicillin | antibacterial drug; drug allergen; epitope | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chloramphenicol | | C-nitro compound; carboxamide; diol; organochlorine compound | antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
vincristine | | acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid | antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
ethinyl estradiol | | 17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound | xenoestrogen | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
apomorphine | | aporphine alkaloid | alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cephalothin | | azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes | antibacterial drug; antimicrobial agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
kanamycin a | | kanamycins | bacterial metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
levodopa | | amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid | allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
methicillin | | penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
colchicine | | alkaloid; colchicine | anti-inflammatory agent; gout suppressant; mutagen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
oxacillin | | penicillin | antibacterial agent; antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ampicillin | | beta-lactam antibiotic; penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
triamcinolone acetonide | | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone | anti-allergic agent; anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
phencyclidine | | benzenes; piperidines | anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
dichloroacetic acid | | monocarboxylic acid; organochlorine compound | astringent; marine metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methylprednisolone | | 6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
penicillin v | | penicillin allergen; penicillin | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
isosorbide dinitrate | | glucitol derivative; nitrate ester | nitric oxide donor; vasodilator agent | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
ergotamine | | peptide ergot alkaloid | alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
neostigmine bromide | | bromide salt | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nafcillin | | penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methohexital | | acetylenic compound; barbiturates | drug allergen; intravenous anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pirinitramide | | nitrile | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
edrophonium bromide | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
azacitidine | | N-glycosyl-1,3,5-triazine; nucleoside analogue | antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
galantamine | | benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound | antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
betamethasone | | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dextropropoxyphene | | 1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate | mu-opioid receptor agonist; opioid analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ketobemidone | | piperidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlormethiazole | | thiazoles | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methamphetamine | | amphetamines; secondary amine | central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lithium carbonate | | carbonate salt; lithium salt | antimanic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
acetylcysteine | | acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid | antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
erythromycin | | cyclic ketone; erythromycin | | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
levonorgestrel | | 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound | contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lormetazepam | | 1,4-benzodiazepinone; organochlorine compound | sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
vinblastine | | | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
ethambutol | | ethanolamines; ethylenediamine derivative | antitubercular agent; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
vancomycin | | glycopeptide | antibacterial drug; antimicrobial agent; bacterial metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
metylperon | | aromatic ketone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
spectinomycin | | cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound | antibacterial drug; antimicrobial agent; bacterial metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dronabinol | | benzochromene; diterpenoid; phytocannabinoid; polyketide | cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
benperidol | | aromatic ketone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlordesmethyldiazepam | | benzodiazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
stavudine | | dihydrofuran; nucleoside analogue; organic molecular entity | antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
doxifluridine | | organofluorine compound; pyrimidine 5'-deoxyribonucleoside | antimetabolite; antineoplastic agent; prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dicloxacillin | | dichlorobenzene; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
streptomycin | | antibiotic antifungal drug; antibiotic fungicide; streptomycins | antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cladribine | | organochlorine compound; purine 2'-deoxyribonucleoside | antineoplastic agent; immunosuppressive agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
carbenicillin | | penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
floxacillin | | penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
beclomethasone dipropionate | | 11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; enone; glucocorticoid; propanoate ester; steroid ester | anti-arrhythmia drug; anti-asthmatic drug; anti-inflammatory drug; prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
olsalazine | | azobenzenes; dicarboxylic acid | non-steroidal anti-inflammatory drug; prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
terodiline | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
1-(4-carboxyphenyl)-3,3-dimethyltriazene | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zalcitabine | | pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
metocurine iodide | | aromatic ether | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
apazone | | benzotriazines | non-steroidal anti-inflammatory drug; uricosuric drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
selegiline | | selegiline; terminal acetylenic compound | geroprotector | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cephalexin | | beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
isosorbide-5-mononitrate | | glucitol derivative; nitrate ester | nitric oxide donor; vasodilator agent | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
cephapirin | | cephalosporin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pregnanolone | | 3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid | human metabolite; intravenous anaesthetic; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
du-21220 | | benzyl alcohols; polyphenol; secondary alcohol; secondary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ribostamycin | | amino cyclitol glycoside; aminoglycoside antibiotic | antibacterial drug; antimicrobial agent; metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefazolin | | beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles | antibacterial drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
halofenate | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amoxicillin | | penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
timolol | | timolol | anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
indoramin | | tryptamines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
toloxatone | | oxazolidinone; primary alcohol; toluenes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zidovudine | | azide; pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
sisomicin | | amino cyclitol glycoside; aminoglycoside antibiotic; beta-L-arabinoside; monosaccharide derivative | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amdinocillin | | penicillin | antibacterial drug; antiinfective agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tobramycin | | amino cyclitol glycoside | antibacterial agent; antimicrobial agent; toxin | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
paclitaxel | | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
etoposide | | beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound | antineoplastic agent; DNA synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ticarcillin | | penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
trimazosin | | N-arylpiperazine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fenclorac | | | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
ribavirin | | 1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide | anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
adinazolam | | triazolobenzodiazepine | anticonvulsant; antidepressant; anxiolytic drug; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amikacin | | alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide | antibacterial drug; antimicrobial agent; nephrotoxin | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tolamolol | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cephradine | | beta-lactam antibiotic allergen; cephalosporin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methyldopa | | L-tyrosine derivative; non-proteinogenic L-alpha-amino acid | alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tocainide | | monocarboxylic acid amide | anti-arrhythmia drug; local anaesthetic; sodium channel blocker | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sulbenicillin | | penicillin | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sq-11725 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
diltiazem | | 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate | antihypertensive agent; calcium channel blocker; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
vecuronium bromide | | organic bromide salt; quaternary ammonium salt | muscle relaxant; neuromuscular agent; nicotinic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
meptazinol | | azepanes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sufentanil | | anilide; ether; piperidines; thiophenes | anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
torsemide | | aminopyridine; N-sulfonylurea; secondary amino compound | antihypertensive agent; loop diuretic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
medroxalol | | salicylamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
epirubicin | | aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefmetazole | | cephalosporin | antibacterial drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
lorcainide | | acetamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
idarubicin | | anthracycline antibiotic; deoxy hexoside; monosaccharide derivative | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ceforanide | | cephalosporin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
piperacillin | | penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
paroxetine | | aromatic ether; benzodioxoles; organofluorine compound; piperidines | antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
captopril | | alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
cefoperazone | | cephalosporin | antibacterial drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
atracurium | | diester; quaternary ammonium ion | muscle relaxant; nicotinic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
moxalactam | | cephalosporin; oxacephem | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
endralazine | | benzamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefadroxil anhydrous | | cephalosporin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
encainide | | benzamides; piperidines | anti-arrhythmia drug; sodium channel blocker | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pefloxacin | | fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone | antibacterial drug; antiinfective agent; DNA synthesis inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
alfentanil | | monocarboxylic acid amide; piperidines | central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
miglustat | | piperidines; tertiary amino compound | anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefotetan | | | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
recainam | | | | 2005 | 2008 | 18.0 | medium | 0 | 0 | 0 | 3 | 0 | 0 |
lovastatin | | delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring) | anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
flupirtine | | aminopyridine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
enoximone | | aromatic ketone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
idazoxan | | benzodioxine; imidazolines | alpha-adrenergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
remoxipride | | dimethoxybenzene | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pravastatin | | 3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic) | anticholesteremic drug; environmental contaminant; metabolite; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bambuterol | | carbamate ester; phenylethanolamines | anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
atomoxetine | | aromatic ether; secondary amino compound; toluenes | adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amifloxacin | | quinolines | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
trospectomycin | | dioxanes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
finasteride | | 3-oxo steroid; aza-steroid; delta-lactam | androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sematilide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
esmolol | | aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
clinafloxacin | | quinolines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
adefovir | | 6-aminopurines; ether; phosphonic acids | antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
loxiglumide | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sparfloxacin | | fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tebufelone | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cidofovir anhydrous | | phosphonic acids; pyrimidone | anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tiagabine | | beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes | anticonvulsant; GABA reuptake inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mibefradil | | tetralins | T-type calcium channel blocker | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
topotecan | | pyranoindolizinoquinoline | antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bromfenac | | aromatic amino acid; benzophenones; organobromine compound; substituted aniline | non-narcotic analgesic; non-steroidal anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gemcitabine | | organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ibutilide | | benzenes; organic amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
aripiprazole | | aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone | drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
remifentanil | | alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester | intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lamivudine | | monothioacetal; nucleoside analogue; oxacycle; primary alcohol | allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
irinotecan | | carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound | antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
valsartan | | biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ibandronic acid | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ziprasidone | | 1,2-benzisothiazole; indolones; organochlorine compound; piperazines | antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zanamivir | | guanidines | antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zolmitriptan | | oxazolidinone; tryptamines | anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tiludronic acid | | organochlorine compound | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
tirofiban | | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cisatracurium | | diester; quaternary ammonium ion | muscle relaxant; nicotinic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fosinoprilat | | L-proline derivative; phosphinic acids | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
trovafloxacin | | | | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
cefprozil | | cephalosporin; semisynthetic derivative | antibacterial drug | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
iopamidol | | benzenedicarboxamide; organoiodine compound; pentol | environmental contaminant; radioopaque medium; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
imipramine n-oxide | | dibenzooxazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ritipenem | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
flomoxef | | N-acyl-amino acid; organonitrogen heterocyclic antibiotic; oxacephem | antibacterial drug | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dexloxiglumide | | glutamic acid derivative | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
intoplicine | | pyridoindole | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
repaglinide | | piperidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
telmisartan | | benzimidazoles; biphenyls; carboxybiphenyl | angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
inogatran | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dexfenfluramine | | fenfluramine | appetite depressant; serotonergic agonist; serotonin uptake inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
ethinyl estradiol-17-sulfate | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
ethinylestradiol-3-sulfate | | 17beta-hydroxy steroid; steroid sulfate | antineoplastic agent; estrogen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefcanel | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
zoledronic acid | | 1,1-bis(phosphonic acid); imidazoles | bone density conservation agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
epristeride | | steroid acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
talinolol | | ureas | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
flunoxaprofen | | 1,3-benzoxazoles; monocarboxylic acid; organofluorine compound | antirheumatic drug; hepatotoxic agent; non-steroidal anti-inflammatory drug; protein kinase C agonist | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
denaverine | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
diprafenone | | aromatic compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nebivolol | | chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
uk 68798 | | aromatic ether; sulfonamide; tertiary amino compound | anti-arrhythmia drug; potassium channel blocker | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ljc 10627 | | carbapenems; organic sulfide; pyrazolotriazole | antibacterial drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
dexrazoxane | | razoxane | antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
voriconazole | | conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug | P450 inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
betamipron | | organonitrogen compound; organooxygen compound | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
bufuralol | | benzofurans | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
panipenem | | organic molecular entity | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
perindoprilat | | dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound | antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
7-hydroxystaurosporine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methotrimeprazine | | phenothiazines; tertiary amine | anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
9-aminocamptothecin | | pyranoindolizinoquinoline | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sch 34343 | | | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
squalamine | | bile acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
atovaquone | | hydroxy-1,2-naphthoquinone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
rivastigmine | | carbamate ester; tertiary amino compound | cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
frovatriptan | | carbazoles | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
eletriptan | | indoles; N-alkylpyrrolidine; sulfone | non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
rosiglitazone | | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
flunisolide | | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone | anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
clarithromycin | | macrolide antibiotic | antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
mci 9038 | | peptide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
imipenem, anhydrous | | beta-lactam antibiotic allergen; carbapenems; zwitterion | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bosentan anhydrous | | primary alcohol; pyrimidines; sulfonamide | antihypertensive agent; endothelin receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
asulacrine | | acridines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hydroxycotinine | | N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
quinaprilat | | dicarboxylic acid; isoquinolines; tertiary carboxamide | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
2-hydroxyimipramine | | dibenzoazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ecteinascidin 743 | | acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound | alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
almotriptan | | indoles; sulfonamide; tertiary amine | non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mk 0663 | | bipyridines; organochlorine compound; sulfone | cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gefitinib | | aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound | antineoplastic agent; epidermal growth factor receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methotrexate | | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tamsulosin | | 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide | alpha-adrenergic antagonist; antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sulbactam | | penicillanic acids | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dilevalol | | 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
docetaxel | | hydrate; secondary alpha-hydroxy ketone | antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
irofulven | | cyclohexenones | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ym 872 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
levofloxacin | | 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic | antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ertapenem | | carbapenemcarboxylic acid; pyrrolidinecarboxamide | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dx 8951 | | pyranoindolizinoquinoline | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cilomilast | | methoxybenzenes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
conivaptan | | benzazepine | aquaretic; vasopressin receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tezosentan | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sabarubicin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
moxifloxacin | | aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone | antibacterial drug | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
clevidipine | | dihydropyridine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
solifenacin | | isoquinolines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
xamoterol | | morpholines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
naproxen | | methoxynaphthalene; monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
abanoquil | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
anidulafungin | | antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
atropine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ropivacaine | | piperidinecarboxamide; ropivacaine | local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
melagatran | | azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound | anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ezlopitant | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tesaglitazar | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bms204352 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fosfluconazole | | conazole antifungal drug; triazole antifungal drug; triazoles | prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cp 101,606 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nsc-89199 | | carbamate ester; organochlorine compound; steroid phosphate | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
phenethicillin | | penicillin allergen; penicillin | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
acivicin | | isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound | antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
bortezomib | | amino acid amide; L-phenylalanine derivative; pyrazines | antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ritonavir | | 1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas | antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
quinidine | | cinchona alkaloid | alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
meropenem | | alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide | antibacterial agent; antibacterial drug; drug allergen | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
cefoxitin | | beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
digitoxin | | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
moxalactam disodium | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
saquinavir | | L-asparagine derivative; quinolines | antiviral drug; HIV protease inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pancuronium | | acetate ester; steroid ester | cholinergic antagonist; muscle relaxant; nicotinic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
rocuronium | | 3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound | drug allergen; muscle relaxant; neuromuscular agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
abacavir | | 2,6-diaminopurines | antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
netilmicin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
miglitol | | piperidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
linezolid | | acetamides; morpholines; organofluorine compound; oxazolidinone | antibacterial drug; protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tolterodine | | tertiary amine | antispasmodic drug; muscarinic antagonist; muscle relaxant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
darifenacin | | 1-benzofurans; monocarboxylic acid amide; pyrrolidines | antispasmodic drug; muscarinic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fluticasone propionate | | 11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester | adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
acarbose | | amino cyclitol; glycoside | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tacrolimus | | macrolide lactam | bacterial metabolite; immunosuppressive agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cerivastatin | | dihydroxy monocarboxylic acid; pyridines; statin (synthetic) | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
rosuvastatin | | dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide | anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cocaine | | benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid | adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
clindamycin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fosfomycin | | epoxide; phosphonic acids | antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zithromax | | macrolide antibiotic | antibacterial drug; environmental contaminant; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
bms 214662 | | benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes | antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
eptifibatide | | homodetic cyclic peptide; macrocycle; organic disulfide | anticoagulant; platelet aggregation inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gs 4071 | | acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound | antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
decitabine | | 2'-deoxyribonucleoside | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sm 8668 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
teniposide | | aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
troxacitabine | | carbohydrate derivative; nucleobase-containing molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefamandole | | cephalosporin; semisynthetic derivative | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tiazofurin | | 1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide | antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
melphalan | | L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound | alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sitafloxacin | | fluoroquinolone antibiotic; quinolines; quinolone antibiotic | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tenofovir | | nucleoside analogue; phosphonic acids | antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dibekacin | | kanamycins | antibacterial agent; protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
micafungin | | antibiotic antifungal drug; echinocandin | antiinfective agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefpiramide | | carboxylic acid; cephalosporin | antibacterial drug | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mezlocillin | | penicillin allergen; penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tropisetron | | indolyl carboxylic acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
leuprolide | | oligopeptide | anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fludarabine | | purine nucleoside | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
propylthiouracil | | pyrimidinethione | antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
etomidate | | ethyl ester; imidazoles | intravenous anaesthetic; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mercaptopurine | | aryl thiol; purines; thiocarbonyl compound | anticoronaviral agent; antimetabolite; antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cotinine | | N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid | antidepressant; biomarker; human xenobiotic metabolite; plant metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
methimazole | | 1,3-dihydroimidazole-2-thiones | antithyroid drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
drotaverin | | isoquinolines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
digoxin | | cardenolide glycoside; steroid saponin | anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cancidas | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lincomycin | | carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound | antimicrobial agent; bacterial metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
thiopental | | barbiturates | anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hmr 3647 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nelarabine | | beta-D-arabinoside; monosaccharide derivative; purine nucleoside | antineoplastic agent; DNA synthesis inhibitor; prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine | | aromatic ether | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dolasetron | | indolyl carboxylic acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
or 1259 | | hydrazone; nitrile; pyridazinone | anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gestodene | | steroid | estrogen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
quinine | | cinchona alkaloid | antimalarial; muscle relaxant; non-narcotic analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
isepamicin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lamifiban | | N-acylglycine | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
telavancin | | glycopeptide | antibacterial drug; antimicrobial agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
susalimod | | | | 2005 | 2005 | 19.0 | high | 0 | 0 | 0 | 1 | 0 | 0 |
sitagliptin | | triazolopyrazine; trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tolcapone | | 2-nitrophenols; benzophenones; catechols | antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
quercetin | | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
amphotericin b | | antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic | antiamoebic agent; antiprotozoal drug; bacterial metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
clavulanic acid | | oxapenam | antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pulmicort | | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone | anti-inflammatory drug; bronchodilator agent; drug allergen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
eprosartan | | dicarboxylic acid; imidazoles; thiophenes | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
montelukast | | aliphatic sulfide; monocarboxylic acid; quinolines | anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mivacurium | | isoquinolines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
entacapone | | 2-nitrophenols; catechols; monocarboxylic acid amide; nitrile | antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
paricalcitol | | hydroxy seco-steroid; seco-cholestane | antiparathyroid drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sdz psc 833 | | homodetic cyclic peptide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
l 660,711 | | quinolines | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
indocyanine green | | 1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
codeine | | morphinane alkaloid; organic heteropentacyclic compound | antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cyclosporine | | homodetic cyclic peptide | anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
hydromorphone | | morphinane alkaloid; organic heteropentacyclic compound | mu-opioid receptor agonist; opioid analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nalmefene | | morphinane alkaloid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
naloxone | | morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol | antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
oxycodone | | organic heteropentacyclic compound; semisynthetic derivative | antitussive; mu-opioid receptor agonist; opioid analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
alvocidib | | dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound | antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
morphine | | morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound | anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
cicaprost | | monoterpenoid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dexmedetomidine | | medetomidine | alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
iloprost | | carbobicyclic compound; monocarboxylic acid; secondary alcohol | platelet aggregation inhibitor; vasodilator agent | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
nalbuphine | | organic heteropentacyclic compound | mu-opioid receptor antagonist; opioid analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nateglinide | | phenylalanine derivative | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
vinorelbine | | acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid | antineoplastic agent; photosensitizing agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
romidepsin | | cyclodepsipeptide; heterocyclic antibiotic; organic disulfide | antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | dihydroxy monocarboxylic acid; indoles; organofluorine compound | | 2005 | 2008 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
naltrexone | | cyclopropanes; morphinane-like compound; organic heteropentacyclic compound | antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
morphine-6-glucuronide | | morphinane alkaloid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
butorphanol | | morphinane alkaloid | antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefodizime | | 1,3-thiazoles; cephalosporin; oxime O-ether | antibacterial drug; EC 1.14.18.1 (tyrosinase) inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
methylnaltrexone | | phenanthrenes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefixime | | cephalosporin | antibacterial drug; drug allergen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
indinavir sulfate | | dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide | HIV protease inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
enalaprilat anhydrous | | dicarboxylic acid; dipeptide | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefuroxime | | 3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether | drug allergen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ceftriaxone | | 1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether | antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
cefepime | | cephalosporin; oxime O-ether | antibacterial drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
hr 810 | | cephalosporin; cyclopentapyridine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ceftazidime | | cephalosporin; oxime O-ether | antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefetamet | | cephalosporin | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
famotidine | | 1,3-thiazoles; guanidines; sulfonamide | anti-ulcer drug; H2-receptor antagonist; P450 inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefotaxime | | 1,3-thiazoles; cephalosporin; oxime O-ether | antibacterial drug; drug allergen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
aztreonam | | beta-lactam antibiotic allergen; monobactam | antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
ginkgolide b | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ro 42-5892 | | cyclopropanes; diol; L-histidine derivative; secondary carboxamide; sulfone | antihypertensive agent; EC 3.4.23.15 (renin) inhibitor; peptidomimetic; vasodilator agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
palonosetron | | azabicycloalkane; delta-lactam; organic heterotricyclic compound | antiemetic; serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefatrizine | | amino acid amide; carboxylic acid; cephalosporin; phenols; semisynthetic derivative; triazoles | antibacterial drug; EC 2.7.11.20 (elongation factor 2 kinase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
eniporide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cilastatin | | carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide | EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ixabepilone | | 1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle | antineoplastic agent; microtubule-destabilising agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gavestinel | | | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
azlocillin | | penicillin allergen; penicillin; semisynthetic derivative | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
verlukast | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ceftizoxime | | cephalosporin | antibacterial drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
cefclidin | | cephalosporin; thiadiazoles | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
carumonam | | monobactam | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
nitrofurantoin | | imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic | antibacterial drug; antiinfective agent; hepatotoxic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
eritoran | | lipid As | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dantrolene | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
artesunate | | artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid | antimalarial; antineoplastic agent; ferroptosis inducer | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dexniguldipine | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
napsagatran | | | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
temsirolimus | | macrolide lactam | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ganaxolone | | corticosteroid hormone | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bms188797 | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
azimilide | | imidazolidine-2,4-dione | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
cefozopran | | cephalosporin; imidazopyridazine; thiadiazoles | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
tomopenem | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bb-83698 | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
sb 242235 | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
zotarolimus | | lactam; macrolide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
gentamicin sulfate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bn 52020 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
vindesine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
moxestrol | | 3-hydroxy steroid | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
scopolamine hydrobromide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
bisaramil | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
teicoplanin | | | | 2008 | 2008 | 16.0 | high | 0 | 0 | 0 | 1 | 0 | 0 |
ly-146032 | | heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide | antibacterial drug; bacterial metabolite; calcium-dependent antibiotics | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dalbavancin | | carbohydrate acid derivative; glycopeptide; monosaccharide derivative; semisynthetic derivative | antibacterial drug; antimicrobial agent | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
cetrorelix | | oligopeptide | antineoplastic agent; GnRH antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tetracycline | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
chlortetracycline | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
oxytetracycline, anhydrous | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
minocycline | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
roquinimex | | aromatic amide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
mobic | | 1,3-thiazoles; benzothiazine; monocarboxylic acid amide | analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
mobiflex | | heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine | antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
isoxicam | | benzothiazine; isoxazoles; monocarboxylic acid amide | antirheumatic drug; non-steroidal anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
warfarin | | benzenes; hydroxycoumarin; methyl ketone | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
demeclocycline | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
rolitetracycline | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sudoxicam | | | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
tigecycline | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
acyclovir | | 2-aminopurines; oxopurine | antimetabolite; antiviral drug | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
rifampin | | cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion | angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
clozapine | | benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound | adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dacarbazine | | dacarbazine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
didanosine | | purine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
ganciclovir | | 2-aminopurines; oxopurine | antiinfective agent; antiviral drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
sildenafil | | piperazines; pyrazolopyrimidine; sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
penciclovir | | 2-aminopurines; propane-1,3-diols | antiviral drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
vardenafil | | imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
allopurinol | | nucleobase analogue; organic heterobicyclic compound | antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
leucovorin | | formyltetrahydrofolic acid | Escherichia coli metabolite; mouse metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tegaserod | | carboxamidine; guanidines; hydrazines; indoles | gastrointestinal drug; serotonergic agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
tirapazamine | | aromatic amine; benzotriazines; N-oxide | antibacterial agent; antineoplastic agent; apoptosis inducer | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pelrinone | | | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
aprepitant | | (trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles | antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ceftobiprole | | cephalosporin; thiadiazoles | antimicrobial agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
rifabutin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 35, Issue:2, 2005
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.Journal of pharmaceutical sciences, , Volume: 94, Issue:7, 2005
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
glycerol | | alditol; triol | algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
4-aminopyridine | | aminopyridine; aromatic amine | avicide; orphan drug; potassium channel blocker | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
aspirin | | benzoic acids; phenyl acetates; salicylates | anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent | 1993 | 2023 | 24.5 | low | 1 | 0 | 9 | 0 | 1 | 1 |
dipyridamole | | piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol | adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
furegrelate | | benzofurans | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
glyburide | | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
hexamethonium | | quaternary ammonium salt | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
indomethacin | | aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole | analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
losartan | | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
prazosin | | aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines | alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
tetraethylammonium | | quaternary ammonium ion | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
ticlopidine | | monochlorobenzenes; thienopyridine | anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
phenylephrine | | phenols; phenylethanolamines; secondary amino compound | alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
pyrroles | | pyrrole; secondary amine | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
thiophenes | | mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound | non-polar solvent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
n-heptane | | alkane; volatile organic compound | non-polar solvent; plant metabolite | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
oxazoles | | 1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene | | 1992 | 2019 | 25.6 | low | 3 | 0 | 30 | 7 | 3 | 0 |
hydrazine | | azane; hydrazines | EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor | 1993 | 1996 | 30.0 | low | 0 | 0 | 3 | 0 | 0 | 0 |
ng-nitroarginine methyl ester | | alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor | 1998 | 2003 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
bm 13505 | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
atorvastatin | | aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic) | environmental contaminant; xenobiotic | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
web 2086 | | organonitrogen heterocyclic compound; organosulfur heterocyclic compound | | 1993 | 1999 | 28.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
triazoles | | 1,2,3-triazole | | 1993 | 1999 | 28.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
masoprocol | | nordihydroguaiaretic acid | antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
cremophor el | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
1-hexadecyl-2-acetyl-glycero-3-phosphocholine | | 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine | antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent | 1999 | 2015 | 17.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
thromboxanes | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
phenylalanyl-prolyl-arginine-chloromethyl ketone | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
pd 145065 | | | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
angiotensin ii | | amino acid zwitterion; angiotensin II | human metabolite | 2002 | 2004 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
benzofurans | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
fibrin | | peptide | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
nitroarginine | | guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
arachidonic acid | | icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid | Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite | 1995 | 1999 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
prostaglandin h2 | | olefinic compound; oxylipin; prostaglandins H; secondary alcohol | mouse metabolite | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
prostaglandin d2 | | prostaglandins D | human metabolite; mouse metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
ricinoleic acid | | (9Z)-12-hydroxyoctadec-9-enoic acid | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
sc 560 | | aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles | angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
dinoprostone | | prostaglandins E | human metabolite; mouse metabolite; oxytocic | 1993 | 2023 | 16.0 | low | 0 | 0 | 1 | 0 | 0 | 1 |
dinoprost | | monocarboxylic acid; prostaglandins Falpha | human metabolite; mouse metabolite | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
thromboxane a2 | | epoxy monocarboxylic acid; thromboxanes A | mouse metabolite | 1992 | 2015 | 25.0 | low | 0 | 0 | 8 | 3 | 1 | 0 |
8,11,14-eicosatrienoic acid | | fatty acid 20:3; long-chain fatty acid | fungal metabolite; human metabolite; nutraceutical | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
leukotriene e4 | | amino dicarboxylic acid; L-cysteine thioether; leukotriene; non-proteinogenic L-alpha-amino acid; secondary alcohol | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
8-epi-prostaglandin f2alpha | | F2-isoprostane | biomarker; bronchoconstrictor agent; vasoconstrictor agent | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
thromboxane b2 | | thromboxanes B | human metabolite; mouse metabolite | 1993 | 2003 | 26.3 | low | 0 | 0 | 2 | 1 | 0 | 0 |
sq 30741 | | | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
sq 29548 | | | | 1993 | 1996 | 30.0 | low | 0 | 0 | 3 | 0 | 0 | 0 |
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid | | | | 1992 | 2004 | 27.7 | low | 0 | 0 | 6 | 1 | 0 | 0 |
enalapril | | dicarboxylic acid monoester; dipeptide | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug | 1999 | 1999 | 25.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
7-(3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo(2.2.1)heptan-2-yl)-5-heptenoic acid | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
vapiprost | | | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
prasugrel hydrochloride | | | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
endothelin-1 | | | | 2002 | 2004 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
warfarin | | benzenes; hydroxycoumarin; methyl ketone | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
transforming growth factor beta | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
transforming growth factor alpha | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
cyclosporine | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
Alcoholic Fatty Liver | 0 | | 1997 | 2013 | 19.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
Alcoholic Liver Diseases | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Alloxan Diabetes | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Angina Pectoris | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Angor Pectoris | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Anti-Phospholipid Antibody Syndrome | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Antiphospholipid Syndrome | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Aortic Coarctation | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Apoplexy | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Arteriosclerosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Aspirin Induced Asthma | 0 | | 2015 | 2023 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
Bacterial Infections, Gram-Negative | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Becker Muscular Dystrophy | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Blood Clot | 0 | | 1993 | 2001 | 27.8 | low | 0 | 0 | 3 | 1 | 0 | 0 |
Blood Pressure, High | 0 | | 1995 | 2002 | 26.0 | low | 0 | 0 | 5 | 2 | 0 | 0 |
Brain Vascular Disorders | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Cardiac Diseases | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Cardiac Failure | 0 | | 1999 | 1999 | 25.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
Cardiomyopathies | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Cardiomyopathies, Primary | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Cardiovascular Stroke | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Carotid Arteriopathies, Traumatic | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Carotid Artery Thrombosis | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
Cerebrovascular Disorders | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Cirrhosis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Coarctation of Aorta | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Disease Models, Animal | 0 | | 1993 | 2019 | 24.5 | low | 0 | 0 | 4 | 1 | 1 | 0 |
Elevated Cholesterol | 0 | | 2001 | 2003 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
Endotoxin Shock | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Fetal Resorption | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Fibrosis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Focal Segmental Glomerulosclerosis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Genetic Predisposition | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Glomerulosclerosis, Focal Segmental | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Goldblatt Syndrome | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Graft Occlusion, Vascular | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Gram-Negative Bacterial Infections | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Heart Disease, Ischemic | 0 | | 1994 | 2001 | 28.0 | low | 0 | 0 | 3 | 1 | 0 | 0 |
Heart Diseases | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Heart Failure | 0 | | 1999 | 1999 | 25.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
Hypercholesterolemia | 0 | | 2001 | 2003 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
Hyperlipemia | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Hyperlipidemias | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Hypertension | 0 | | 1995 | 2002 | 26.0 | low | 0 | 0 | 5 | 2 | 0 | 0 |
Hypertension, Pulmonary | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Hypertension, Renovascular | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Hypertriglyceridemia | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Injuries | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Injury, Myocardial Reperfusion | 0 | | 1994 | 1995 | 29.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
Ischemia | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Leg Ulcer | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Liver Diseases, Alcoholic | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Muscle Contraction | 0 | | 1993 | 2001 | 27.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
Muscular Dystrophy, Duchenne | 1 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Myocardial Infarction | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Myocardial Ischemia | 0 | | 1994 | 2001 | 28.0 | low | 0 | 0 | 3 | 1 | 0 | 0 |
Pregnancy | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Pulmonary Hypertension | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Shock, Septic | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Sinus Infections | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
Sinusitis | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
Stasis Ulcer | 0 | | 1998 | 1998 | 26.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
Stroke | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Thrombosis | 0 | | 1993 | 2001 | 27.8 | low | 0 | 0 | 3 | 1 | 0 | 0 |
Varicose Ulcer | 0 | | 1998 | 1998 | 26.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
Wounds and Injuries | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits.Clinical science (London, England : 1979), , Volume: 104, Issue:4, 2003
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 16 Suppl 1, 2001
Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension.Kidney international. Supplement, , Issue:82, 2002
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.Cardiovascular drug reviews, ,Summer, Volume: 19, Issue:2, 2001
Involvement of nitric oxide and potassium channels in the reduction of basal tone produced by blockade of thromboxane A2/prostaglandin H2 receptors in aortic rings of hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 20, Issue:8, 1998
Sympathetic nervous system and hypertension during prolonged TxA2/PGH2 receptor activation in rats.The American journal of physiology, , Volume: 273, Issue:2 Pt 2, 1997
Contribution of constrictor prostanoids to the calcium-dependent basal tone in the aorta from rats with aortic coarctation-induced hypertension: relationship to nitric oxide.The Journal of pharmacology and experimental therapeutics, , Volume: 283, Issue:1, 1997
Effect of ifetroban, a thromboxane A2 receptor antagonist, in stroke-prone spontaneously hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:2, 1996
Dissociation of endothelial cell dysfunction and blood pressure in SHR.The American journal of physiology, , Volume: 269, Issue:1 Pt 2, 1995
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.Cardiovascular drug reviews, ,Summer, Volume: 19, Issue:2, 2001
Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.The Journal of pharmacology and experimental therapeutics, , Volume: 264, Issue:2, 1993
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.Cardiovascular drug reviews, ,Summer, Volume: 19, Issue:2, 2001
A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin.Journal of pharmacological and toxicological methods, , Volume: 35, Issue:1, 1996
Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function.Pharmacology, , Volume: 50, Issue:2, 1995
Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.Journal of cardiovascular pharmacology, , Volume: 22, Issue:4, 1993
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.Cardiovascular drug reviews, ,Summer, Volume: 19, Issue:2, 2001
Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function.Pharmacology, , Volume: 50, Issue:2, 1995
Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs.Journal of cardiovascular pharmacology, , Volume: 24, Issue:3, 1994
Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs.Journal of cardiovascular pharmacology, , Volume: 24, Issue:6, 1994
Antagonism of the Thromboxane-Prostanoid Receptor as a Potential Therapy for Cardiomyopathy of Muscular Dystrophy.Journal of the American Heart Association, , 11-05, Volume: 8, Issue:21, 2019
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 16 Suppl 1, 2001
A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin.Journal of pharmacological and toxicological methods, , Volume: 35, Issue:1, 1996
Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs.Journal of cardiovascular pharmacology, , Volume: 24, Issue:3, 1994
Effect of long-acting thromboxane receptor antagonist (BMS 180,291) on experimental antiphospholipid syndrome.Lupus, , Volume: 3, Issue:5, 1994
Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.Journal of cardiovascular pharmacology, , Volume: 22, Issue:4, 1993
Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits.Clinical science (London, England : 1979), , Volume: 104, Issue:4, 2003
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 16 Suppl 1, 2001
Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension.Kidney international. Supplement, , Issue:82, 2002
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.Cardiovascular drug reviews, ,Summer, Volume: 19, Issue:2, 2001
Involvement of nitric oxide and potassium channels in the reduction of basal tone produced by blockade of thromboxane A2/prostaglandin H2 receptors in aortic rings of hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 20, Issue:8, 1998
Contribution of constrictor prostanoids to the calcium-dependent basal tone in the aorta from rats with aortic coarctation-induced hypertension: relationship to nitric oxide.The Journal of pharmacology and experimental therapeutics, , Volume: 283, Issue:1, 1997
Sympathetic nervous system and hypertension during prolonged TxA2/PGH2 receptor activation in rats.The American journal of physiology, , Volume: 273, Issue:2 Pt 2, 1997
Effect of ifetroban, a thromboxane A2 receptor antagonist, in stroke-prone spontaneously hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:2, 1996
Dissociation of endothelial cell dysfunction and blood pressure in SHR.The American journal of physiology, , Volume: 269, Issue:1 Pt 2, 1995
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.Cardiovascular drug reviews, ,Summer, Volume: 19, Issue:2, 2001
A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin.Journal of pharmacological and toxicological methods, , Volume: 35, Issue:1, 1996
Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function.Pharmacology, , Volume: 50, Issue:2, 1995
Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.Journal of cardiovascular pharmacology, , Volume: 22, Issue:4, 1993
Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function.Pharmacology, , Volume: 50, Issue:2, 1995
Failure of aspirin to interfere with the cardioprotective effects of ifetroban.European journal of pharmacology, , Dec-27, Volume: 271, Issue:2-3, 1994
Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs.Journal of cardiovascular pharmacology, , Volume: 24, Issue:6, 1994
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.Cardiovascular drug reviews, ,Summer, Volume: 19, Issue:2, 2001
Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function.Pharmacology, , Volume: 50, Issue:2, 1995
Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs.Journal of cardiovascular pharmacology, , Volume: 24, Issue:6, 1994
Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs.Journal of cardiovascular pharmacology, , Volume: 24, Issue:3, 1994
Long-term Use (1)
Pharmacokinetics (3)
Article | Year |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7 | 2008 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. Journal of pharmaceutical sciences, , Volume: 94, Issue:7 | 2005 |
Inhibition of prostaglandin D2 clearance in rat hepatocytes by the thromboxane receptor antagonists daltroban and ifetroban and the thromboxane synthase inhibitor furegrelate. Biochemical pharmacology, , Aug-15, Volume: 66, Issue:4 | 2003 |
Bioavailability (1)
Dosage (2)